Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB8 | P26012 | 6/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.44 |
| ▸ | ITGAV | P06756 | 11/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594404 | 1.00 | ITGB8 (0.44) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7596620 | 1.00 | ITGB8 (0.44) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7595308 | 0.91 | ITGAV (0.46) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7593605 | 0.91 | ITGAV (0.46) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7590552 | 0.85 | ITGAV (0.43) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7590648 | 0.85 | ITGAV (0.43) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7557082 | 0.85 | ITGAV (0.43) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7589610 | 0.85 | ITGAV (0.47) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL7591361 | 0.85 | ITGAV (0.47) | ITGB8ITGB6ITGA5ITGAVITGB3 | |
| SCHEMBL4382525 | 0.85 | ITGB3 (0.46) | ITGB8ITGB6ITGA5ITGAVITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | KAKEN PHARMACEUTICALS | 2002-04-25 | — | — | US | claimed |
| US-6255321-B1 | ANTIALLERGENS; RESPIRATRORY SYSTEM DISORDERS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | LTB4R2, LTB4R, CYSLTR2 | ITGB8 1058/4885ITGB6 516/4885ITGA5 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.